SCHEMBL5225020

SCHEMBL5225020

CCOC(=O)CN(Cc1cccc(OCCc2nc(-c3cccs3)oc2C)c1)S(=O)(=O)N(C)C

nearest known ligand 0.51

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 20/20 0.51
PPARG P37231 19/20 0.51
PPARD Q03181 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5228175 0.93 PPARA (0.51) PPARAPPARG
SCHEMBL5441436 0.92 PPARG (0.59) PPARAPPARGPPARD
SCHEMBL5229512 0.92 PPARG (0.51) PPARAPPARGPPARD
SCHEMBL5228126 0.91 PPARG (0.58) PPARAPPARGPPARD
SCHEMBL5225909 0.90 PPARG (0.47) PPARAPPARGPPARD
SCHEMBL5230875 0.88 PPARG (0.65) PPARAPPARG
SCHEMBL5226601 0.88 PPARG (0.57) PPARAPPARGPPARD
SCHEMBL5230986 0.86 PPARG (0.54) PPARAPPARG
SCHEMBL5439905 0.85 PPARA (0.49) PPARAPPARGPPARD
SCHEMBL5428415 0.85 PPARA (0.58) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same CRYSTAL GENOMICS, INC. (KR) 2007-11-01 US disclosed
EP-1778654-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME Crystalgenomics, Inc. (KR) 2007-05-02 EP disclosed
WO-2006006832-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME CRYSTALGENOMICS, INC. (KR) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same SULT2A1, SPTLC2, SGMS2 PPARA 190/4885PPARG 399/4885PPARD 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.